Takamasa Nukui
University of Toyama
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Takamasa Nukui.
Journal of Stroke & Cerebrovascular Diseases | 2012
Koji Hirano; Shutaro Takashima; Nobuhiro Dougu; Yoshiharu Taguchi; Takamasa Nukui; Hirohumi Konishi; Shigeo Toyoda; Isao Kitajima; Kortaro Tanaka
BACKGROUND We studied the usefulness of hemostatic biomarkers in assessing the pathology of thrombus formation, subtype diagnosis, prognosis in the acute phase of cerebral infarction, and differences between various hemostatic biomarkers. METHODS Our study included 69 patients with acute cerebral infarction who had been hospitalized within 2 days of stroke onset. Fibrin monomer complex (FMC), soluble fibrin (SF), D-dimer, thrombin-antithrombin III complex, fibrinogen, antithrombin III, and fibrin/fibrinogen degradation products (FDPs) were assayed as hemostatic biomarkers on days 1, 2, 3, and 7 of hospitalization. RESULTS In the cardioembolic (CE) stroke group, FMC and SF levels were significantly higher on days 1 and 2 of hospitalization, and D-dimer levels were significantly higher on day 1 of hospitalization, compared to the noncardioembolic (non-CE) stroke group. FDP levels were significantly higher at all times in the CE group compared to the non-CE group. Neither the National Institute of Health Stroke Scale (NIHSS) used during hospitalization nor the modified Rankin Scale (mRS) used at discharge found any significant correlations to hemostatic biomarkers, but the NIHSS score during hospitalization was significantly higher in the CE group than in the non-CE group. CONCLUSIONS Measurements of hemostatic biomarkers, such as FMC, SF, and D-dimer on the early stage of cerebral infarction are useful for distinguishing between CE and non-CE stroke.
Rinsho Shinkeigaku | 2018
Tomohiro Hayashi; Takamasa Nukui; Shutaro Takashima; Yuji Nakatsuji; Sayuri Shima; Tatsuro Mutoh
We report a case of acute disseminated encephalomyelitis (ADEM) concomitant with polyneuropathy associated with anti-lactosylceramide antibody. A 68-year-old man was admitted to our hospital with ophthalmoparesis, bulbar palsy, tetraplegia after suffering from upper respiratory infection and headache. Subsequently, he developed respiratory failure requiring mechanical ventilation. Fluid-attenuated inversion recovery (FLAIR) MRI showed high intensities in the pons and medulla, and a nerve conduction study revealed motor-dominant axonal polyneuropathy. Although the laboratory tests revealed the presence of anti-lactosylceramide antibody in his serum, he was diagnosed with acute disseminated encephalomyelitis concomitant with polyneuropathy. Whereas the intensive treatment with corticosteroids, plasmapharesis, and high-dose intravenous immunoglobulin (IVIg) brought a moderate improvement, his tetraparesis continued to exist.
Rinsho Shinkeigaku | 2018
Hirofumi Konishi; Yoshiharu Taguchi; Mamoru Yamamoto; Takamasa Nukui; Nobuhiro Dougu; Yuji Nakatsuji
A 63-year-old man developed a syndrome of cauda equine, with the numbness which is a left lower extremity from the left buttocks, weakness of left leg, and a dysfunction of bladder and bowel. Enhanced MRI revealed the enhancement of lower cauda equine, and a nerve conduction test revealed decreased F-wave persistency in the tibial nerve and increased F-wave latency in the peroneal nerve on the both sides. M-proteinemia was admitted and myeloma was suspected. By a biopsy of a vertebral arch, we diagnosed with diffuse large B-cell lymphoma. We treated with dexamethasone and R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone (prednisolone)), then the symptom was improved. In case of caude equine syndrome with M-proteinemia, a possibility of the malignant lymphoma should also be considered.
Frontiers in Aging Neuroscience | 2018
Koji Ishikuro; Nobuhiro Dougu; Takamasa Nukui; Mamoru Yamamoto; Yuji Nakatsuji; Satoshi Kuroda; Isao Matsushita; Hiroshi Nishimaru; Mariana Ferreira Pereira de Araújo; Hisao Nishijo
Parkinson’s disease (PD) is a neurodegenerative disorder with motor and non-motor symptoms due to degeneration of dopaminergic neurons. The current pharmacological treatments induce complications associated with long-term use. However, current stimulation techniques for PD treatment, such as deep brain stimulation (DBS), are too invasive. In this context, non-invasive brain stimulation including transcranial direct current stimulation (tDCS) may be a safe and effective alternative treatment for PD. We previously reported that anodal tDCS over the frontal polar area (FPA) improved motor functions in heathy subjects. Therefore, in the present study, effects of tDCS over the FPA on motor and cognitive functions of PD patients were analyzed. Nine PD patients (3 men and 6 women) participated in this cross over study with three tDCS protocols; anodal, cathodal or sham tDCS over the FPA. Each tDCS protocol was applied for 1 week (5 times/week). Before and after each protocol, motor and cognitive functions of the patients were assessed using Unified PD Rating Scale [UPDRS (part III: motor examination)], Fugl Meyer Assessment set (FMA), Simple Test for Evaluating hand Function (STEF) and Trail Making Test A (TMT-A). The results indicated that anodal stimulation significantly decreased scores of motor disability in UPDRS-III compared with sham and cathodal stimulation, and significantly increased scores of motor functions in FMA compared with sham stimulation. Furthermore, anodal stimulation significantly decreased time to complete a motor task requiring high dexterity in STEF compared with those requiring low and medium levels of dexterity. In addition, anodal stimulation significantly decreased time to complete the TMT-A task, which requires executive functions, compared with sham stimulation. To the best of our knowledge, this is the first clinical research reporting that tDCS over the FPA successfully improved the motor and non-motor functions in PD patients. These findings suggest that tDCS over the FPA might be a useful alternative for the treatment of PD patients.
Internal Medicine | 2011
Yoshiharu Taguchi; Shutaro Takashima; Takamasa Nukui; Kortaro Tanaka
Internal Medicine | 2010
Yoshiharu Taguchi; Shutaro Takashima; Takamasa Nukui; Kortaro Tanaka
Rinshō shinkeigaku Clinical neurology | 2014
Takamasa Nukui; Shutaro Takashima; Yoshiharu Taguchi; Nobuhiro Dougu; Hirofumi Konishi; Kortaro Tanaka
Nosotchu | 2011
Yoshiharu Taguchi; Shutaro Takashima; Nobuhiro Dougu; Koji Hirano; Takamasa Nukui; Hirofumi Konishi; Koji Yoshida; Kortaro Tanaka
Journal of the Neurological Sciences | 2018
Takamasa Nukui; Yurika Nakayama; Mamoru Yamamoto; Yoshiharu Taguchi; Nobuhiro Dougu; Hirofumi Konishi; Tomohiro Hayashi; Yuji Nakatsuji
Journal of the Neurological Sciences | 2017
Yoshiharu Taguchi; S. Takashima; Nobuhiro Dougu; Takamasa Nukui; Hirofumi Konishi; Tomohiro Hayashi; Mamoru Yamamoto; Yuji Nakatsuji